Biological markers of respiratory diseases


如何引用文章

全文:

全文:

Биологические маркеры при респираторных заболеваниях. -
×

作者简介

A Chuchalin

Email: pulmo_fmba@mail.ru

参考

  1. Cochrane methodology registry. In: The Cochrane Library. Oxford 2001.
  2. Sacket D.L., Straus S.E. Finding and applying evidence during clinical rounds. JAMA 1998; 280: 1336-1338.
  3. Флетчер Р., Флетчер С., Вагнер Э. Клиническая эпидемиология (основы доказательной медицины). М: Медиа Сфера 1998; 352.
  4. De Gruttola V.G., Clax P., DeMets D.L. et al. Consideration in the evaluation of surrogate endpоints in clinical trials. Summary of a National Institutes of Health workshop. Control Clin Trials 2001; 22 (5): 485-502.
  5. Woodruff P.G., Modrek B., Choy D.F. et al. T-helper type 2-driven inflammation defines major sub phenotypes of asthma. Am J Respir Crit Care Med 2009; 180 (5): 388-395.
  6. Micheel C.M., Ball J.R., eds. Committee on Qualification of Biomarkes and Surrogate Endpoints in Chronic Disease; Institute of Medicine. Evaluation of Biomarkes and Surrogate Endpoints in Chronic Disease. 2010.
  7. Waterer G. Modern Diagnosis of Community Acquired and Viral Pneumonia: Beyond Conventional Microbiology Culture. Proceedings American Thoracic Society, Postgraduate course #3,4/12.
  8. Porcel J.M., Ruiz-González A., Falguera M. et al. Contribution of a pleural antigen assay (Binax NOW) to the diagnosis of pneumococcal pneumonia. Chest 2007; 131 (5): 1442-1447.
  9. Murdoch D.R., Laing R.T., Cook J.M. The NOW S. pneumoniae urinary antigen test positivity rate 6 weeks after pneumonia onset and among patients with COPD. Clin Infect Dis 2003; 37 (1): 153-154.
  10. Rello J., Ausina V., Ricart M. et al. Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. 1993. Chest 2009; 104 (4): 1230-1235.
  11. Perlino C. Alcoholism, leukopenia, and pneumococcal sepsis. Am Rev Respir Dis 1984; 132: 757-760.
  12. Carlos W.G., Hage Ch.A. Advances in the non-culture based laboratory diagnosis of cryptococcus and endemic molds. Curr Fungal Infect Rep 2012; 6 (3): 215-220.
  13. Cattamanchi A. Moving beyond smear and culture: rapid diagnosis of tuberculosis and identification of drug resistance. Proceedings American Thoracic Society, 2013. Posgratuate course #3, 1-18.
  14. Light R.W., Lee G., Lee Y.C.G. Textbook of Pleural Disease. Hodder Arnold 2008; 650.
  15. Light R.W., Lee Y.C. Pneumothorax, Chylothorax, Hemothorax, Fibrothorax. In Murray and Nadel's Textbook of respiratory disease. 5th ed. 2010; 2400.
  16. Боткин С.П. Клинические лекции. Под ред. А.Л. Мясникова. 1952.
  17. Sethi S., Wrona C., Eschberger K. et al. Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. AJRCCM 2008; 177 (5): 491-495.
  18. Pierrakos C., Vincent J.L. Sepsis biomarkers: a review. Critical care 2010; 14 (1): 15.
  19. Calfee C. Novel biomarkers in ARDS. Proceedings American Thoracic Society 2013. Postgratuate course #3.
  20. Agrawal S. et al. COPD Pulmonary disease, chronic obstructive, severe early-onset. AJRCCM 2013 (in press).

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Consilium Medicum, 2014

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house